Biliary tract intraductal papillary mucinous neoplasm: Report of 19 cases

Xing Wang, Yun-Qiang Cai, Yong-Hua Chen, Xu-Bao Liu

Xing Wang, Yun-Qiang Cai, Yong-Hua Chen, Xu-Bao Liu, Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Author contributions: Wang X and Liu XB designed the research; Wang X, Cai YQ, and Chen YH performed the research and analyzed the data; Wang X and Cai YQ wrote the paper; Liu XB proofread and revised the manuscript; all authors approved the version to be published.

Supported by The Research Special Fund for Public Welfare Industry of Health, No. 201202007.

Conflict-of-interest: There is no conflict of interest of the authors.

Data sharing: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Xu-Bao Liu, MD, PhD, Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu 610041, Sichuan Province, China. shoubulele@gmail.com
Telephone: +86-28-85422477
Fax: +86-28-85422474
Received: September 2, 2014
Peer-review started: September 3, 2014
First decision: November 14, 2014
Revised: November 21, 2014
Accepted: January 8, 2015
Article in press: January 8, 2015
Published online: April 14, 2015

Abstract

AIM: To gain a better understanding of biliary tract intraductal papillary mucinous neoplasm (BT-IPMN).

METHODS: From January 2000 to December 2013, 19 cases of BT-IPMN were retrospectively identified from a total of 343 biliary tract tumors resected in our single institution. Demographic characteristics, clinical data, pathology, surgical strategies, and long-term follow-up were analyzed.

RESULTS: The mean age of the 19 BT-IPMN cases was 53.8 years (range: 25-74 years). The most common symptom was abdominal pain (15/19; 78.9%), followed by jaundice (7/19; 36.8%). Cholangitis was associated with most (16/19; 84.2%) of the BT-IPMN cases. Macroscopically visible mucin was detected in all 19 patients, based on original surgical reports. The most common abnormal preoperative imaging findings for BT-IPMN were bile duct dilation (19/19; 100%) and intraluminal masses (10/19; 52.6%). Thirteen (68.4%) cases involved the intrahepatic bile duct and hilum. We performed left hepatectomy in 11/19 (57.9%), right hepatectomy in 2/19 (10.5%), bile duct resection in 4/19 (21.1%), and pancreatoduodenectomy in 1/19 (5.3%) patients. One (5.3%) patient was biopsied and received a choledochojejunostomy because of multiple tumors involving the right extrahepatic and left intrahepatic bile ducts. Histology showed malignancy in 10/19 (52.6%) patients. The overall median survival was 68 mo. The benign cases showed a non-significant trend towards improved survival compared to malignant cases (68 mo vs 48 mo, P = 0.347). The patient without tumor resection died of liver failure 22 mo after palliative surgery.

CONCLUSION: BT-IPMN is a rare biliary entity. Complete resection of the tumor is associated with good survival, even in patients with malignant disease.

Key words: Biliary tract; Cystic tumor; Intraductal papillary mucinous neoplasm; Mucinous tumor; Papillary tumor

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Our study involved a large number of patients with biliary tract intraductal papillary mucinous neoplasm (BT-IPMN) from a large Chinese institution. We summarized the clinical features, radiologic findings, pathology, surgical strategies, and long-term follow-up of these patients to achieve a better understanding of this rare disease. Our findings indicated that BT-IPMN is a rare biliary entity and complete resection of the tumor is associated with good survival, even in patients with malignant disease.

Wang X, Cai YQ, Chen YH, Liu XB. Biliary tract intraductal papillary mucinous neoplasm: Report of 19 cases. World J Gastroenterol 2015; 21(14): 4261-4267 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i14/4261.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i14.4261

INTRODUCTION
In the past decade, biliary tract intraductal papillary mucinous neoplasm (BT-IPMN) has been increasingly recognized as a unique type of biliary neoplasm, coinciding with widespread acceptance of the nomenclature of pancreatic intraductal papillary mucinous neoplasm (P-IPMN)[1-3]. As the name suggests, BT-IPMN is known to be a biliary counterpart of P-IPMN, but with its own separate identity[4-6]. BT-IPMN is histologically defined as a mucinous and papillary neoplasm, with a clear origin from the biliary epithelium, with solitary or diffuse intraductal growth[7]. It is a rare neoplasm involving the intra- and extrahepatic biliary tract and is characterized by mucin-secreting papillary and/or cystic lesions. BT-IPMN is recognized as a precursor of invasive carcinoma (tubular adenocarcinoma or mucinous carcinoma) and 40%-80% of resected BT-IPMNs contain invasive components[10-12]. BT-IPMN has a more favorable prognosis compared with conventional cholangiocarcinoma[13,14]. The number of reports of BT-IPMN with strict histopathologic criteria is limited. Moreover, most of the data regarding BT-IPMN are from retrospective studies with small samples. There is still controversy about several aspects of BT-IPMN, and the clinicopathologic characteristics, surgical strategies, and prognosis of BT-IPMN are largely unclear[12,17].

Our study involved a large number of patients with BT-IPMN from a large Chinese institution. The purpose of this study was to summarize the demographic and clinical features, radiologic findings, pathology, surgical strategies, and long-term follow-up of patients with BT-IPMN for a better understanding of this rare disease.

MATERIALS AND METHODS
Patient selection
From January 2000 to December 2013, 19 patients with BT-IPMN were retrospectively identified in our institution. All diagnoses were established using strict histopathologic criteria for BT-IPMN: a mucinous and papillary neoplasm demonstrating clear origin from the biliary epithelium, with solitary or diffuse intraductal growth[1]. We excluded mucinous cystic neoplasms of the liver (with ovarian or mesenchymal stroma)[15], lesions originating from the periamplillary region of the duodenum[16], and lesions without microscopic or macroscopic mucin secretion. All 19 BT-IPMNs were histologically classified into benign (low- or middle-grade dysplasia) and malignant (high-grade dysplasia or invasive carcinoma)[17].

Data collection
Clinical data were obtained from the electronic medical records or external medical reports. Demographic characteristics, clinical presentation, preoperative evaluation, pathology, surgical therapy, postoperative course, and long-term outcomes were included. Postoperative complications (all events recorded within 30 d after surgery) were included in our prospective complication database. Survival was measured from the date of operation to date of death or of last follow-up. We conducted telephone interviews and/or outpatient interview to follow-up these patients. This study was approved by the Ethics Committee of Sichuan University.

Statistical analysis
Survival probability was estimated using the Kaplan-Meier method. Statistical analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, United States). A P < 0.05 was considered statistically significant.
a left hepatectomy (Table 4). One patient required pancreaticoduodenectomy for tumor clearance and another received biopsy and choledochojejunostomy for multiple tumors of the extrahepatic and right and left intrahepatic bile ducts. No deaths occurred within 30 d after surgery, though 4/19 (21.1%) patients had postoperative complications. Bile leakage occurred with postoperative pneumonia in a 68-year-old patient who underwent local bile duct excision, resulting in a prolonged (65 d) hospitalization and readmission, which was cured through percutaneous drainage and antibiotics. In addition, three patients had postoperative complications that were cured by conservative therapy. Lymphadenectomy was routinely performed, however, no lymph node metastasis was detected in our series.

**Gross appearance**

The mean tumor size was 3.5 cm (range: 0.5-12 cm). The gross appearance of BT-IPMN varies with size. Smaller BT-IPMN tumors typically present as an intraluminal mass (Figure 2), though they can appear as cyst-like bile duct dilatation. Intraluminal growing intraductal papillary neoplasms (10/19; 52.6%) and visible mucin (19/19; 100%) on the surface of the tumor were typical characteristics of BT-IPMN.

**Histopathology**

BT-IPMN is known to be classified into four histopathologic subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) based on morphologic appearance and mucin staining properties, which are identical to those of P-IPMN. Microscopically, BT-IPMN was mucinous with papillary proliferation of biliary epithelial cells and intraductal growth. Mucin was observed with histopathology (Figure 3) in all 19 patients, and 10/19 detected by postoperative histologic examination. CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen.

| Table 1 Patient demographics (n = 19) |
|--------------------------------------|
| **Feature**                          | **n (%)** |
| Age (yr)                             |           |
| ≤40                                  | 3 (15.8)  |
| 40-50                                | 4 (21.1)  |
| 50-60                                | 6 (31.6)  |
| ≥60                                  | 6 (31.6)  |
| Sex                                  |           |
| Male                                 | 11 (57.9) |
| Female                               | 8 (42.1)  |

| Table 2 Clinical features of biliary tract intraductal papillary mucinous neoplasm (n = 19) |
|------------------------------------------------------------------------------------------|
| **Feature**                          | **n (%)** |
| Presenting symptoms                   |           |
| Abdominal pain                        | 15 (78.9) |
| Jaundice                              | 7 (36.8)  |
| Weight loss                           | 3 (15.8)  |
| None                                  | 1 (5.3)   |
| Schistosomiasis¹                      | 4 (21.1)  |
| Presence of cholangitis               | 16 (84.2) |
| Repeated episodes cholangitis         | 6 (31.6)  |
| Location                              |           |
| Intrahepatic and hilum               | 13 (68.4) |
| Extrahepatic                          | 5 (26.3)  |
| Multifocal                            | 1 (5.3)   |
| Serum chemistry                       |           |
| Elevated CEA (> 3.4 ng/dL)            | 5 (26.3)  |
| Elevated CA 19-9 (> 22 U/mL)          | 8 (42.1)  |

¹Detected by postoperative histologic examination.

| Table 3 Imaging features of biliary tract intraductal papillary mucinous neoplasm (n = 19) |
|------------------------------------------------------------------------------------------|
| **Feature**                          | **n (%)** |
| Biliary stones (n = 12)                 |           |
| Proximal                              | 10 (52.6) |
| Proximal and distal                   | 2 (10.5)  |
| Cholecystolithiasis                   | 0 (0.0)   |
| Dilated bile duct (n = 19)            |           |
| Proximal                              | 6 (31.6)  |
| Proximal and distal                   | 13 (68.4) |
| Cyst                                  | 10 (52.6) |
| Lesion                                | 10 (52.6) |
| Liver atrophy                         | 7 (36.8)  |
| Imaging examination                   |           |
| Ultrasonography                       | 19 (100)  |
| Computed tomography                   | 15 (78.9) |
| Magnetic resonance imaging            | 12 (63.2) |
| Intraoperative choledochoscopy         | 8 (42.1)  |
| Endoscopic retrograde cholangiography | 4 (21.1)  |

Figure 1 Imaging presentation of biliary tract intraductal papillary mucinous neoplasm. A: Magnetic resonance cholangiography shows dilation of proximal biliary tract and a filling defect in the extrahepatic biliary tract (arrow); B: Magnetic resonance imaging shows an intraluminal polypoid lesion originating from the extrahepatic biliary tract (arrow).
BT-IPMN case was due to subsequent small cell lung cancer after 26 mo.

DISCUSSION

Although wide consensus has not yet been reached, BT-IPMN has been increasingly recognized as a unique type of biliary neoplasm and a biliary counterpart of P-IPMN[$^1,7$]. The World Health Organization recognized intraductal papillary neoplasm of the bile duct (IPNB) as a distinct pathological entity in 2010[$^10$]. Ohtsuka et al[$^16$] suggested that IPNB with or without macroscopically visible mucin secretion differed in terms of pathologic features. In our study, BT-IPMN was defined as mucinous papillary neoplasm, demonstrating a clear origin from the biliary epithelium[$^1$], and excluded lesions (such as IPNB) without microscopic or macroscopic mucin secretion. To some extent, BT-IPMN is a presumed subtype of IPNB, which has more similarity to P-IPMN than IPNB itself[$^16$].

BT-IPMN shares some radiologic and clinicopathologic features with P-IPMN, but important differences between them may still exist. The frequency of malignancy is higher in patients with BT-IPMN (64%-89%) than in those with P-IPMN (23%-30%)[$^{1,2,7,18}$]. Consistent with previous studies, the rate of malignant BT-IPMN in our series was > 50%. There are several reasons for the higher rate of malignancy in patients with BT-IPMN. First,
as several recent reports have suggested, the majority of BT-IPMNs are of an intestinal or pancreatobiliary subtype, resembling those of main-duct-type P-IPMN, which is more aggressive than branch-duct P-IPMN[1,7,10]. Second, the biliary tract and the main pancreatic duct have identical embryologic development from the hepatic diverticulum in the foregut mesoderm[2,27].

In the present study, BT-IPMN mostly presented in patients aged 50–70 years, which is consistent with several other studies[1,3,7,10,20]. Although more male BT-IPMNs patients were found in our study, no difference was found in sex distribution based on previous reports[1,7,10]. The most common presenting symptom was abdominal pain, probably due to biliary stones, cholangitis, or high pressure of biliary tract causing mucin hypersecretion, which are associated with BT-IPMN[10,21]. Intraluminal hypersecretion of mucin from the bile duct may intermittently impede bile flow, leading to repeated episodes of cholangitis. Repeated cholangitis was found in approximately 32% of patients with BT-IPMN in our study, as a typical clinical presentation of BT-IPMN. Nearly 63% of BT-IPMNs were associated with biliary stones; most of which were proximal biliary stones. These findings indicate that the process of inflammatory stimulation may play a role in the development of BT-IPMN. BT-IPMNs were predominantly located in the intrahepatic bile duct and hilum, though the primary site of tumor origin does not affect the progress or prognosis of the disease[10,20,21]. Dilated bile ducts, intraluminal lesions, and/or gross cystic dilatation originating from the biliary tract are the most common abnormal preoperative imaging findings in BT-IPMN. Simultaneous proximal and distal bile duct dilation was found in approximately 68% of patients with BT-IPMN in our study. It has diagnostic significance, as with diffused pancreatic duct dilation for P-IPMN. The large amount of mucin discharged into the duct system leads to diffuse duct dilation.

Surgery is the first choice of treatment for patients with BT-IPMN without distant metastasis[22]. Determination of the optimal surgical strategy depends on the site and extent of the lesions. Intraoperative choledochoscopy and surgical margin frozen sectioning are performed to assess tumor location and extension, including superficial spreading along the biliary epithelium[23]. Hepatobiliary should be performed for tumors located in the intrahepatic bile duct, whereas pancreatoduodenectomy and bile duct resection are performed for tumors located in the extrahepatic bile duct. Jarnagin et al[24] recommended regional lymphadenectomy for tumors localized in the hilum or distal bile duct. Lymph node metastasis is rare in benign BT-IPMN, and is less common in patients with invasive carcinoma arising from BT-IPMN, compared with conventional cholangiocarcinoma[8]. No patient in our series suffered from lymph node metastases. Portal vein resection is an option for tumors with blood vessel involvement[8]. Theoretically, resection of the entire biliary tract by liver transplantation could be a better option for curative treatment of diffuse BT-IPMN. Palliative surgery was performed in one patient with diffuse BT-IPMN in our study.

Only one patient died 22 mo after palliative surgery, with poorer survival than the overall median survival of 68 mo. Rocha et al[10] found that R0 resection was associated with better median survival than R1 resection. The median survival for the benign group in our study appeared better than for malignant cases, though the lack of significance may have been due to the relatively short follow-up period and small sample size. However, the difference may reflect an intrinsic difference in tumor biology. Complete tumor resection is associated with good survival, even in patients with malignant BT-IPMN.

The small number of patients in the present study prevented us from making strong conclusions. Moreover, a major limitation was the retrospective nature of the study. Diagnostic modalities for BT-IPMN, including imaging and pathology, have varied at different times. Nevertheless, due to the scarcity of patients, we are still justified in speculating on the trends that can be observed in this limited set of data. More multicenter prospective studies are necessary to identify the clinical and pathologic characteristics of BT-IPMN.

In conclusion, BT-IPMN is a rare biliary entity. Complete resection of the tumor is associated with good survival, even in patients with malignant BT-IPMN.

**COMMENTS**

**Background**

In the past decade, biliary tract intraductal papillary mucinous neoplasm (BT-IPMN) has been increasingly recognized as a unique type of biliary neoplasm, coinciding with widespread acceptance of the nomenclature of pancreatic IPMN. BT-IPMN is a rare neoplasm involving the intra- and extrahepatic biliary tracts and is characterized by mucin-secreting papillary and/or cystic lesions.
However, there is still controversy over several aspects of BT-IPMN.

**Research frontiers**

BT-IPMN is a rare biliary entity. The number of reports of BT-IPMN with strict histopathologic criteria is limited. Most of the data regarding BT-IPMN are from retrospective studies with small samples. There is still controversy surrounding several aspects of BT-IPMN, and clinicopathologic characteristics, surgical strategies, and prognosis are largely unclear.

**Innovations and breakthroughs**

This study involved a large number of patients with BT-IPMN from a large Chinese institution. The authors summarized the clinical features, radiologic findings, pathology, surgical strategies, and long-term follow-up of patients with BT-IPMN, and achieved a better understanding of this rare disease. The findings indicate that BT-IPMN is indeed a rare biliary entity and complete resection of the tumor is associated with good survival, even in patients with malignant disease.

**Applications**

BT-IPMN is a rare biliary entity. Complete resection of the tumor is associated with good survival, even in patients with malignant disease.

**Terminology**

BT-IPMN is historically defined as a mucinous and papillary neoplasm demonstrating a clear origin from the biliary epithelium, with solitary or diffuse intraductal growth.

**Peer-review**

This is a very interesting paper. The data are clearly presented and extensively discussed on the basis of the recent relevant international literature.

**REFERENCES**

1. Barton JG, Barrett DA, Maricevich MA, Schnellдорfer T, Wood CM, Smyrk TC, Baron TH, Sarr MG, Donohue JH, Farnell MB, Kendrick ML, Nagorney DM, Reid Lombardo KM, Que FG. Intraductal papillary mucinous neoplasm of the biliary tract: a real disease? HPB (Oxford) 2009; 11: 684-691 [PMID: 20495657 DOI: 10.1016/j.hpb.2009.01.022]

2. Selabas GM, Barton JG, Smyrk TC, Barrett DA, Khan S, Kendrick ML, Reid-Lombardo KM, Donohue JH, Nagorney DM, Que FG. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm. J Am Coll Surg 2012; 214: 27-32 [PMID: 22112419 DOI: 10.1016/j.jamcollsurg.2011.09.025]

3. Zen Y, Fujii T, Ito K, Nakamura K, Minato H, Kasashima S, Kurumaya H, Katayanagi K, Kawashima A, Masuda S, Niwa H, Mitsui T, Asada Y, Miura S, Ohtsuka M, Yoshitomi H, Furukawa K, Takeuchi D, Takayashiki T, Suda K, Takenaka Y, Kondo S, Katoh H. Mucin-secreting bile duct neoplasm characterized by clinicopathological resemblance to intraductal papillary mucinous tumor of the pancreas. Hepatobiliary Pancreat Dis Int 2011; 10: 98-106 [PMID: 21825660]

4. Nakashima A, Sumida Y, Abo T, Nagasaki T, Takeshita H, Fukuoka H, Sawai T, Tanaka K, Yatsukata T, Nagayasu T. Patient outcome and prognostic factors in intraductal cholangiocarcinoma after hepatectomy. Hepatogastroenterology 2007; 54: 2337-2342 [PMID: 18265660]

5. Zen Y, Pedica F, Patcha VR, Capelli P, Zamboni G, Casaril A, Quaglia A, Nakamura Y, Heaton N, Portmann B. Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol 2011; 24: 1079-1089 [PMID: 21516077 DOI: 10.1038/modpathol.2011.71]

6. Ohbutsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, Furukawa K, Takesuchi D, Takayashiki T, Suda K, Takeno S, Kondo Y, Miyazaki M. Similarities and differences between intraductal papillary tumors of the bile duct with and without macroscopically visible mucin secretion. Am J Surg Pathol 2011; 35: 512-521 [PMID: 21421069 DOI: 10.1097/PAS.0b013e3182103f36]

7. Tanaka M, Fernandez-del Castillo C, Asday V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamazaki K. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012; 12: 183-197 [PMID: 22683731 DOI: 10.1016/j.pan.2012.04.004]

8. Schnellдорfer T, Sarr MG, Nagorney DM, Zhang L, Smyrk TC, Qin R, Chari ST, Farnell MB. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg 2008; 143: 639-646; discussion 646 [PMID: 18645105 DOI: 10.1001/archsurg.143.7.639]

9. Nakamura Y. A novel approach to biliary tract pathology based on similarities to pancreatic counterparts: is the biliary tract an incomplete pancreas? Pathol Int 2010; 60: 419-429 [PMID: 20518896 DOI: 10.1111/j.1440-1827.2010.02543.x]

10. Kim KM, Lee JK, Shin JU, Lee KH, Lee KT, Sung JY, Jang KT, Heo JS, Choi SH, Choi DW, Lim JH. Clinicopathologic features of intraductal papillary neoplasm of the bile duct according to histologic subtype. J Am Gastroenterol 2012; 107: 118-125 [PMID: 21946282 DOI: 10.1038/jag.2011.316]

11. Van SX, Xu Y, Chen MY, Yang XB, Wang AQ, He L, Zhao HT, Sang XT. Intraductal papillary neoplasm of the bile duct. World J Gastroenterol 2013; 19: 8595-8604 [PMID: 24379576 DOI: 10.3748/wjg.v19.i33.8595]
Wang X et al. Biliary tract intraductal papillary mucinous neoplasm

10.3748/wjg.v19.i46.8595

22 Kim JK, Hwang HK, Park JS, Cho SI, Yoon DS, Chi HS. Left hemihepatectomy and caudate lobectomy and complete extrahepatic bile duct resection using transduodenal approach for hilar cholangiocarcinoma arising from biliary papillomatosis. J Surg Oncol 2008; 98: 139-142 [PMID: 18521837 DOI: 10.1002/jso.21089]

23 Ohtsuka M, Shimizu H, Kato A, Yoshitomi H, Furukawa K, Tsuyuguchi T, Sakai Y, Yokosuka O, Miyazaki M. Intraductal papillary neoplasms of the bile duct. Int J Hepatol 2014; 2014: 459091 [PMID: 24949206 DOI: 10.1155/2014/459091]

24 Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, DeMatteo RP, D’Angelica M, Koea J, Blumgart LH. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241: 703-712; discussion 712-714 [PMID: 15849506]

P- Reviewer: Frider B, Ooi LL  S- Editor: Ma YJ
L- Editor: AmEditor  E- Editor: Zhang DN
